APO Research
Talk to an analyst

APO RESEARCH · REPORT

Osteoarthritis Pain Drugs

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.

Selected research

Industry Research

Osteoarthritis Pain Drugs Industry Research Report 2026

2 January 2026149 pages

Choose your research edition.

Industry ResearchOsteoarthritis Pain Drugs Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Osteoarthritis Pain Drugs Industry Growth and Trends Forecast to 2032128 pages · $3,450 USDMarket StructureGlobal Osteoarthritis Pain Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Osteoarthritis Pain Drugs Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Osteoarthritis Pain Drugs Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.

The major players in global Methylcyclohexane market include Pfizer, Johnson & Johnson, GlaxoSmithKline, etc. The top 3 players occupy about 45% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Oral is the main type, with a share over 50%. Personal Care is the main application, which holds a share about 90%.

Report Scope

Read the full market overview

This report quantifies the global Osteoarthritis Pain Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (M Dose), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Dose) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Osteoarthritis Pain Drugs Market by Company

Pfizer

Bayer

SK Chemicals

GSK

Sanofi

Crystal Genomics

Johnson & Johnson

Sino Biopharmaceutical

Haohai Biological

Zhejiang Chengyi Pharmaceutical

Freda

Bright Future

Jingfeng Pharmaceutical

Chugai Pharmaceutical

Mikasa Seiyaku

Taisho Pharmaceutical

Seikagaku Corporation

GlaxoSmithKline

Eli Lilly

Novartis

Horizon Pharma

Abbott

Mylan

Daiichi Sankyo

TEVA

Almatica Pharma

Astellas Pharma

Tide Pharmaceutical

Iroko Pharmaceuticals

Hengrui Pharmaceutical

Osteoarthritis Pain Drugs Segment by Type

Oral

Injection

External

Osteoarthritis Pain Drugs Segment by Application

Medical Care

Personal Care

Osteoarthritis Pain Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Osteoarthritis Pain Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Osteoarthritis Pain Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Osteoarthritis Pain Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Osteoarthritis Pain Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Osteoarthritis Pain Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Osteoarthritis Pain Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Osteoarthritis Pain Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Osteoarthritis Pain Drugs Sales (M Dose) of Manufacturers (2021-2026) Table 7. Global Osteoarthritis Pain Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Osteoarthritis Pain Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Osteoarthritis Pain Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Osteoarthritis Pain Drugs Average Price (US$/Dose) of Manufacturers (2021-2026) Table 11. Global Osteoarthritis Pain Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Osteoarthritis Pain Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Osteoarthritis Pain Drugs, Product Type & Application Table 14. Global Osteoarthritis Pain Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Osteoarthritis Pain Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Pfizer Company Information Table 19. Pfizer Business Overview Table 20. Pfizer Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 21. Pfizer Osteoarthritis Pain Drugs Product Portfolio Table 22. Pfizer Recent Developments Table 23. Bayer Company Information Table 24. Bayer Business Overview Table 25. Bayer Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 26. Bayer Osteoarthritis Pain Drugs Product Portfolio Table 27. Bayer Recent Developments Table 28. SK Chemicals Company Information Table 29. SK Chemicals Business Overview Table 30. SK Chemicals Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 31. SK Chemicals Osteoarthritis Pain Drugs Product Portfolio Table 32. SK Chemicals Recent Developments Table 33. GSK Company Information Table 34. GSK Business Overview Table 35. GSK Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 36. GSK Osteoarthritis Pain Drugs Product Portfolio Table 37. GSK Recent Developments Table 38. Sanofi Company Information Table 39. Sanofi Business Overview Table 40. Sanofi Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 41. Sanofi Osteoarthritis Pain Drugs Product Portfolio Table 42. Sanofi Recent Developments Table 43. Crystal Genomics Company Information Table 44. Crystal Genomics Business Overview Table 45. Crystal Genomics Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 46. Crystal Genomics Osteoarthritis Pain Drugs Product Portfolio Table 47. Crystal Genomics Recent Developments Table 48. Johnson & Johnson Company Information Table 49. Johnson & Johnson Business Overview Table 50. Johnson & Johnson Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 51. Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolio Table 52. Johnson & Johnson Recent Developments Table 53. Sino Biopharmaceutical Company Information Table 54. Sino Biopharmaceutical Business Overview Table 55. Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 56. Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 57. Sino Biopharmaceutical Recent Developments Table 58. Haohai Biological Company Information Table 59. Haohai Biological Business Overview Table 60. Haohai Biological Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 61. Haohai Biological Osteoarthritis Pain Drugs Product Portfolio Table 62. Haohai Biological Recent Developments Table 63. Zhejiang Chengyi Pharmaceutical Company Information Table 64. Zhejiang Chengyi Pharmaceutical Business Overview Table 65. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 66. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 67. Zhejiang Chengyi Pharmaceutical Recent Developments Table 68. Freda Company Information Table 69. Freda Business Overview Table 70. Freda Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 71. Freda Osteoarthritis Pain Drugs Product Portfolio Table 72. Freda Recent Developments Table 73. Bright Future Company Information Table 74. Bright Future Business Overview Table 75. Bright Future Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 76. Bright Future Osteoarthritis Pain Drugs Product Portfolio Table 77. Bright Future Recent Developments Table 78. Jingfeng Pharmaceutical Company Information Table 79. Jingfeng Pharmaceutical Business Overview Table 80. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 81. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 82. Jingfeng Pharmaceutical Recent Developments Table 83. Chugai Pharmaceutical Company Information Table 84. Chugai Pharmaceutical Business Overview Table 85. Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 86. Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 87. Chugai Pharmaceutical Recent Developments Table 88. Mikasa Seiyaku Company Information Table 89. Mikasa Seiyaku Business Overview Table 90. Mikasa Seiyaku Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 91. Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolio Table 92. Mikasa Seiyaku Recent Developments Table 93. Taisho Pharmaceutical Company Information Table 94. Taisho Pharmaceutical Business Overview Table 95. Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 96. Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 97. Taisho Pharmaceutical Recent Developments Table 98. Seikagaku Corporation Company Information Table 99. Seikagaku Corporation Business Overview Table 100. Seikagaku Corporation Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 101. Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolio Table 102. Seikagaku Corporation Recent Developments Table 103. GlaxoSmithKline Company Information Table 104. GlaxoSmithKline Business Overview Table 105. GlaxoSmithKline Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 106. GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolio Table 107. GlaxoSmithKline Recent Developments Table 108. Eli Lilly Company Information Table 109. Eli Lilly Business Overview Table 110. Eli Lilly Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 111. Eli Lilly Osteoarthritis Pain Drugs Product Portfolio Table 112. Eli Lilly Recent Developments Table 113. Novartis Company Information Table 114. Novartis Business Overview Table 115. Novartis Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 116. Novartis Osteoarthritis Pain Drugs Product Portfolio Table 117. Novartis Recent Developments Table 118. Horizon Pharma Company Information Table 119. Horizon Pharma Business Overview Table 120. Horizon Pharma Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 121. Horizon Pharma Osteoarthritis Pain Drugs Product Portfolio Table 122. Horizon Pharma Recent Developments Table 123. Abbott Company Information Table 124. Abbott Business Overview Table 125. Abbott Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 126. Abbott Osteoarthritis Pain Drugs Product Portfolio Table 127. Abbott Recent Developments Table 128. Mylan Company Information Table 129. Mylan Business Overview Table 130. Mylan Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 131. Mylan Osteoarthritis Pain Drugs Product Portfolio Table 132. Mylan Recent Developments Table 133. Daiichi Sankyo Company Information Table 134. Daiichi Sankyo Business Overview Table 135. Daiichi Sankyo Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 136. Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolio Table 137. Daiichi Sankyo Recent Developments Table 138. TEVA Company Information Table 139. TEVA Business Overview Table 140. TEVA Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 141. TEVA Osteoarthritis Pain Drugs Product Portfolio Table 142. TEVA Recent Developments Table 143. Almatica Pharma Company Information Table 144. Almatica Pharma Business Overview Table 145. Almatica Pharma Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 146. Almatica Pharma Osteoarthritis Pain Drugs Product Portfolio Table 147. Almatica Pharma Recent Developments Table 148. Astellas Pharma Company Information Table 149. Astellas Pharma Business Overview Table 150. Astellas Pharma Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 151. Astellas Pharma Osteoarthritis Pain Drugs Product Portfolio Table 152. Astellas Pharma Recent Developments Table 153. Tide Pharmaceutical Company Information Table 154. Tide Pharmaceutical Business Overview Table 155. Tide Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 156. Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 157. Tide Pharmaceutical Recent Developments Table 158. Iroko Pharmaceuticals Company Information Table 159. Iroko Pharmaceuticals Business Overview Table 160. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 161. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolio Table 162. Iroko Pharmaceuticals Recent Developments Table 163. Hengrui Pharmaceutical Company Information Table 164. Hengrui Pharmaceutical Business Overview Table 165. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 166. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 167. Hengrui Pharmaceutical Recent Developments Table 168. Global Osteoarthritis Pain Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 169. Global Osteoarthritis Pain Drugs Sales by Region (2021-2026) & (M Dose) Table 170. Global Osteoarthritis Pain Drugs Sales Market Share by Region (2021-2026) Table 171. Global Osteoarthritis Pain Drugs Sales by Region (2027-2032) & (M Dose) Table 172. Global Osteoarthritis Pain Drugs Sales Market Share by Region (2027-2032) Table 173. Global Osteoarthritis Pain Drugs Revenue by Region (2021-2026) & (US$ Million) Table 174. Global Osteoarthritis Pain Drugs Revenue Market Share by Region (2021-2026) Table 175. Global Osteoarthritis Pain Drugs Revenue by Region (2027-2032) & (US$ Million) Table 176. Global Osteoarthritis Pain Drugs Revenue Market Share by Region (2027-2032) Table 177. North America Osteoarthritis Pain Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 178. North America Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 179. North America Osteoarthritis Pain Drugs Sales by Country (2027-2032) & (M Dose) Table 180. North America Osteoarthritis Pain Drugs Revenue by Country (2021-2026) & (US$ Million) Table 181. North America Osteoarthritis Pain Drugs Revenue by Country (2027-2032) & (US$ Million) Table 182. Europe Osteoarthritis Pain Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 183. Europe Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 184. Europe Osteoarthritis Pain Drugs Sales by Country (2027-2032) & (M Dose) Table 185. Europe Osteoarthritis Pain Drugs Revenue by Country (2021-2026) & (US$ Million) Table 186. Europe Osteoarthritis Pain Drugs Revenue by Country (2027-2032) & (US$ Million) Table 187. Asia Pacific Osteoarthritis Pain Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 188. Asia Pacific Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 189. Asia Pacific Osteoarthritis Pain Drugs Sales by Country (2027-2032) & (M Dose) Table 190. Asia Pacific Osteoarthritis Pain Drugs Revenue by Country (2021-2026) & (US$ Million) Table 191. Asia Pacific Osteoarthritis Pain Drugs Revenue by Country (2027-2032) & (US$ Million) Table 192. South America Osteoarthritis Pain Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 193. South America Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 194. South America Osteoarthritis Pain Drugs Sales by Country (2027-2032) & (M Dose) Table 195. South America Osteoarthritis Pain Drugs Revenue by Country (2021-2026) & (US$ Million) Table 196. South America Osteoarthritis Pain Drugs Revenue by Country (2027-2032) & (US$ Million) Table 197. Middle East and Africa Osteoarthritis Pain Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 198. Middle East and Africa Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 199. Middle East and Africa Osteoarthritis Pain Drugs Sales by Country (2027-2032) & (M Dose) Table 200. Middle East and Africa Osteoarthritis Pain Drugs Revenue by Country (2021-2026) & (US$ Million) Table 201. Middle East and Africa Osteoarthritis Pain Drugs Revenue by Country (2027-2032) & (US$ Million) Table 202. Global Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (M Dose) Table 203. Global Osteoarthritis Pain Drugs Sales by Type (2027-2032) & (M Dose) Table 204. Global Osteoarthritis Pain Drugs Sales Market Share by Type (2021-2026) Table 205. Global Osteoarthritis Pain Drugs Sales Market Share by Type (2027-2032) Table 206. Global Osteoarthritis Pain Drugs Revenue by Type (2021-2026) & (US$ Million) Table 207. Global Osteoarthritis Pain Drugs Revenue by Type (2027-2032) & (US$ Million) Table 208. Global Osteoarthritis Pain Drugs Revenue Market Share by Type (2021-2026) Table 209. Global Osteoarthritis Pain Drugs Revenue Market Share by Type (2027-2032) Table 210. Global Osteoarthritis Pain Drugs Price by Type (2021-2026) & (US$/Dose) Table 211. Global Osteoarthritis Pain Drugs Price by Type (2027-2032) & (US$/Dose) Table 212. Global Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (M Dose) Table 213. Global Osteoarthritis Pain Drugs Sales by Application (2027-2032) & (M Dose) Table 214. Global Osteoarthritis Pain Drugs Sales Market Share by Application (2021-2026) Table 215. Global Osteoarthritis Pain Drugs Sales Market Share by Application (2027-2032) Table 216. Global Osteoarthritis Pain Drugs Revenue by Application (2021-2026) & (US$ Million) Table 217. Global Osteoarthritis Pain Drugs Revenue by Application (2027-2032) & (US$ Million) Table 218. Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2021-2026) Table 219. Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2027-2032) Table 220. Global Osteoarthritis Pain Drugs Price by Application (2021-2026) & (US$/Dose) Table 221. Global Osteoarthritis Pain Drugs Price by Application (2027-2032) & (US$/Dose) Table 222. Key Raw Materials Table 223. Raw Materials Key Suppliers Table 224. Osteoarthritis Pain Drugs Distributors List Table 225. Osteoarthritis Pain Drugs Customers List Table 226. Osteoarthritis Pain Drugs Industry Trends Table 227. Osteoarthritis Pain Drugs Industry Drivers Table 228. Osteoarthritis Pain Drugs Industry Restraints Table 229. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Osteoarthritis Pain Drugs Product Image Figure 5. Global Osteoarthritis Pain Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Osteoarthritis Pain Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Osteoarthritis Pain Drugs Sales (2021-2032) & (M Dose) Figure 8. Global Osteoarthritis Pain Drugs Average Price (US$/Dose) & (2021-2032) Figure 9. Oral Product Image Figure 10. Injection Product Image Figure 11. External Product Image Figure 12. Medical Care Product Image Figure 13. Personal Care Product Image Figure 14. Global Osteoarthritis Pain Drugs Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Osteoarthritis Pain Drugs, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Osteoarthritis Pain Drugs Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Osteoarthritis Pain Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Osteoarthritis Pain Drugs Sales by Region in 2025 Figure 20. Global Osteoarthritis Pain Drugs Revenue by Region in 2025 Figure 21. North America Osteoarthritis Pain Drugs Market Size by Country in 2025 Figure 22. North America Osteoarthritis Pain Drugs Sales Market Share by Country (2021-2032) Figure 23. North America Osteoarthritis Pain Drugs Revenue Market Share by Country (2021-2032) Figure 24. United States Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Osteoarthritis Pain Drugs Market Size by Country in 2025 Figure 28. Europe Osteoarthritis Pain Drugs Sales Market Share by Country (2021-2032) Figure 29. Europe Osteoarthritis Pain Drugs Revenue Market Share by Country (2021-2032) Figure 30. Germany Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Osteoarthritis Pain Drugs Market Size by Country in 2025 Figure 41. Asia Pacific Osteoarthritis Pain Drugs Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Osteoarthritis Pain Drugs Revenue Market Share by Country (2021-2032) Figure 43. China Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Osteoarthritis Pain Drugs Market Size by Country in 2025 Figure 52. South America Osteoarthritis Pain Drugs Sales Market Share by Country (2021-2032) Figure 53. South America Osteoarthritis Pain Drugs Revenue Market Share by Country (2021-2032) Figure 54. Brazil Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Osteoarthritis Pain Drugs Market Size by Country in 2025 Figure 58. Middle East and Africa Osteoarthritis Pain Drugs Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Osteoarthritis Pain Drugs Revenue Market Share by Country (2021-2032) Figure 60. Egypt Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Osteoarthritis Pain Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Osteoarthritis Pain Drugs Sales Market Share by Type (2021-2032) Figure 66. Global Osteoarthritis Pain Drugs Revenue Market Share by Type (2021-2032) Figure 67. Global Osteoarthritis Pain Drugs Price (US$/Dose) by Type (2021-2032) Figure 68. Global Osteoarthritis Pain Drugs Sales Market Share by Application (2021-2032) Figure 69. Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2021-2032) Figure 70. Global Osteoarthritis Pain Drugs Price (US$/Dose) by Application (2021-2032) Figure 71. Osteoarthritis Pain Drugs Value Chain Figure 72. Osteoarthritis Pain Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Osteoarthritis Pain Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Oral
  • Injection
  • External
Applications
  • Medical Care
  • Personal Care
Companies covered
  • Pfizer
  • Bayer
  • SK Chemicals
  • GSK
  • Sanofi
  • Crystal Genomics
  • Johnson & Johnson
  • Sino Biopharmaceutical
  • Haohai Biological
  • Zhejiang Chengyi Pharmaceutical
  • Freda
  • Bright Future
  • Jingfeng Pharmaceutical
  • Chugai Pharmaceutical
  • Mikasa Seiyaku
  • Taisho Pharmaceutical
  • Seikagaku Corporation
  • GlaxoSmithKline
  • Eli Lilly
  • Novartis
  • Horizon Pharma
  • Abbott
  • Mylan
  • Daiichi Sankyo
  • TEVA
  • Almatica Pharma
  • Astellas Pharma
  • Tide Pharmaceutical
  • Iroko Pharmaceuticals
  • Hengrui Pharmaceutical

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Osteoarthritis Pain Drugs Market Size (2021-2032)
  4. 2.2.2 Global Osteoarthritis Pain Drugs Sales (2021-2032)
  5. 2.2.3 Global Osteoarthritis Pain Drugs Market Average Price (2021-2032)
  6. 2.3 Osteoarthritis Pain Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Oral
  9. 2.3.3 Injection
  10. 2.3.4 External
  11. 2.4 Osteoarthritis Pain Drugs by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Medical Care
  14. 2.4.3 Personal Care
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Osteoarthritis Pain Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Osteoarthritis Pain Drugs Sales (M Dose) of Manufacturers (2021-2026)
  3. 3.3 Global Osteoarthritis Pain Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Osteoarthritis Pain Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Osteoarthritis Pain Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Osteoarthritis Pain Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Osteoarthritis Pain Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Osteoarthritis Pain Drugs, Established Date
  9. 3.9 Global Osteoarthritis Pain Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Pfizer
  2. 4.1.1 Pfizer Company Information
  3. 4.1.2 Pfizer Business Overview
  4. 4.1.3 Pfizer Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Pfizer Osteoarthritis Pain Drugs Product Portfolio
  6. 4.1.5 Pfizer Recent Developments
  7. 4.2 Bayer
  8. 4.2.1 Bayer Company Information
  9. 4.2.2 Bayer Business Overview
  10. 4.2.3 Bayer Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Bayer Osteoarthritis Pain Drugs Product Portfolio
  12. 4.2.5 Bayer Recent Developments
  13. 4.3 SK Chemicals
  14. 4.3.1 SK Chemicals Company Information
  15. 4.3.2 SK Chemicals Business Overview
  16. 4.3.3 SK Chemicals Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 SK Chemicals Osteoarthritis Pain Drugs Product Portfolio
  18. 4.3.5 SK Chemicals Recent Developments
  19. 4.4 GSK
  20. 4.4.1 GSK Company Information
  21. 4.4.2 GSK Business Overview
  22. 4.4.3 GSK Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 GSK Osteoarthritis Pain Drugs Product Portfolio
  24. 4.4.5 GSK Recent Developments
  25. 4.5 Sanofi
  26. 4.5.1 Sanofi Company Information
  27. 4.5.2 Sanofi Business Overview
  28. 4.5.3 Sanofi Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Sanofi Osteoarthritis Pain Drugs Product Portfolio
  30. 4.5.5 Sanofi Recent Developments
  31. 4.6 Crystal Genomics
  32. 4.6.1 Crystal Genomics Company Information
  33. 4.6.2 Crystal Genomics Business Overview
  34. 4.6.3 Crystal Genomics Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Crystal Genomics Osteoarthritis Pain Drugs Product Portfolio
  36. 4.6.5 Crystal Genomics Recent Developments
  37. 4.7 Johnson & Johnson
  38. 4.7.1 Johnson & Johnson Company Information
  39. 4.7.2 Johnson & Johnson Business Overview
  40. 4.7.3 Johnson & Johnson Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolio
  42. 4.7.5 Johnson & Johnson Recent Developments
  43. 4.8 Sino Biopharmaceutical
  44. 4.8.1 Sino Biopharmaceutical Company Information
  45. 4.8.2 Sino Biopharmaceutical Business Overview
  46. 4.8.3 Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  48. 4.8.5 Sino Biopharmaceutical Recent Developments
  49. 4.9 Haohai Biological
  50. 4.9.1 Haohai Biological Company Information
  51. 4.9.2 Haohai Biological Business Overview
  52. 4.9.3 Haohai Biological Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Haohai Biological Osteoarthritis Pain Drugs Product Portfolio
  54. 4.9.5 Haohai Biological Recent Developments
  55. 4.10 Zhejiang Chengyi Pharmaceutical
  56. 4.10.1 Zhejiang Chengyi Pharmaceutical Company Information
  57. 4.10.2 Zhejiang Chengyi Pharmaceutical Business Overview
  58. 4.10.3 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  60. 4.10.5 Zhejiang Chengyi Pharmaceutical Recent Developments
  61. 4.11 Freda
  62. 4.11.1 Freda Company Information
  63. 4.11.2 Freda Business Overview
  64. 4.11.3 Freda Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Freda Osteoarthritis Pain Drugs Product Portfolio
  66. 4.11.5 Freda Recent Developments
  67. 4.12 Bright Future
  68. 4.12.1 Bright Future Company Information
  69. 4.12.2 Bright Future Business Overview
  70. 4.12.3 Bright Future Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Bright Future Osteoarthritis Pain Drugs Product Portfolio
  72. 4.12.5 Bright Future Recent Developments
  73. 4.13 Jingfeng Pharmaceutical
  74. 4.13.1 Jingfeng Pharmaceutical Company Information
  75. 4.13.2 Jingfeng Pharmaceutical Business Overview
  76. 4.13.3 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  78. 4.13.5 Jingfeng Pharmaceutical Recent Developments
  79. 4.14 Chugai Pharmaceutical
  80. 4.14.1 Chugai Pharmaceutical Company Information
  81. 4.14.2 Chugai Pharmaceutical Business Overview
  82. 4.14.3 Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  84. 4.14.5 Chugai Pharmaceutical Recent Developments
  85. 4.15 Mikasa Seiyaku
  86. 4.15.1 Mikasa Seiyaku Company Information
  87. 4.15.2 Mikasa Seiyaku Business Overview
  88. 4.15.3 Mikasa Seiyaku Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolio
  90. 4.15.5 Mikasa Seiyaku Recent Developments
  91. 4.16 Taisho Pharmaceutical
  92. 4.16.1 Taisho Pharmaceutical Company Information
  93. 4.16.2 Taisho Pharmaceutical Business Overview
  94. 4.16.3 Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  96. 4.16.5 Taisho Pharmaceutical Recent Developments
  97. 4.17 Seikagaku Corporation
  98. 4.17.1 Seikagaku Corporation Company Information
  99. 4.17.2 Seikagaku Corporation Business Overview
  100. 4.17.3 Seikagaku Corporation Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolio
  102. 4.17.5 Seikagaku Corporation Recent Developments
  103. 4.18 GlaxoSmithKline
  104. 4.18.1 GlaxoSmithKline Company Information
  105. 4.18.2 GlaxoSmithKline Business Overview
  106. 4.18.3 GlaxoSmithKline Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolio
  108. 4.18.5 GlaxoSmithKline Recent Developments
  109. 4.19 Eli Lilly
  110. 4.19.1 Eli Lilly Company Information
  111. 4.19.2 Eli Lilly Business Overview
  112. 4.19.3 Eli Lilly Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Eli Lilly Osteoarthritis Pain Drugs Product Portfolio
  114. 4.19.5 Eli Lilly Recent Developments
  115. 4.20 Novartis
  116. 4.20.1 Novartis Company Information
  117. 4.20.2 Novartis Business Overview
  118. 4.20.3 Novartis Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Novartis Osteoarthritis Pain Drugs Product Portfolio
  120. 4.20.5 Novartis Recent Developments
  121. 4.21 Horizon Pharma
  122. 4.21.1 Horizon Pharma Company Information
  123. 4.21.2 Horizon Pharma Business Overview
  124. 4.21.3 Horizon Pharma Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Horizon Pharma Osteoarthritis Pain Drugs Product Portfolio
  126. 4.21.5 Horizon Pharma Recent Developments
  127. 4.22 Abbott
  128. 4.22.1 Abbott Company Information
  129. 4.22.2 Abbott Business Overview
  130. 4.22.3 Abbott Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Abbott Osteoarthritis Pain Drugs Product Portfolio
  132. 4.22.5 Abbott Recent Developments
  133. 4.23 Mylan
  134. 4.23.1 Mylan Company Information
  135. 4.23.2 Mylan Business Overview
  136. 4.23.3 Mylan Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Mylan Osteoarthritis Pain Drugs Product Portfolio
  138. 4.23.5 Mylan Recent Developments
  139. 4.24 Daiichi Sankyo
  140. 4.24.1 Daiichi Sankyo Company Information
  141. 4.24.2 Daiichi Sankyo Business Overview
  142. 4.24.3 Daiichi Sankyo Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolio
  144. 4.24.5 Daiichi Sankyo Recent Developments
  145. 4.25 TEVA
  146. 4.25.1 TEVA Company Information
  147. 4.25.2 TEVA Business Overview
  148. 4.25.3 TEVA Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  149. 4.25.4 TEVA Osteoarthritis Pain Drugs Product Portfolio
  150. 4.25.5 TEVA Recent Developments
  151. 4.26 Almatica Pharma
  152. 4.26.1 Almatica Pharma Company Information
  153. 4.26.2 Almatica Pharma Business Overview
  154. 4.26.3 Almatica Pharma Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  155. 4.26.4 Almatica Pharma Osteoarthritis Pain Drugs Product Portfolio
  156. 4.26.5 Almatica Pharma Recent Developments
  157. 4.27 Astellas Pharma
  158. 4.27.1 Astellas Pharma Company Information
  159. 4.27.2 Astellas Pharma Business Overview
  160. 4.27.3 Astellas Pharma Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  161. 4.27.4 Astellas Pharma Osteoarthritis Pain Drugs Product Portfolio
  162. 4.27.5 Astellas Pharma Recent Developments
  163. 4.28 Tide Pharmaceutical
  164. 4.28.1 Tide Pharmaceutical Company Information
  165. 4.28.2 Tide Pharmaceutical Business Overview
  166. 4.28.3 Tide Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  167. 4.28.4 Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  168. 4.28.5 Tide Pharmaceutical Recent Developments
  169. 4.29 Iroko Pharmaceuticals
  170. 4.29.1 Iroko Pharmaceuticals Company Information
  171. 4.29.2 Iroko Pharmaceuticals Business Overview
  172. 4.29.3 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  173. 4.29.4 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolio
  174. 4.29.5 Iroko Pharmaceuticals Recent Developments
  175. 4.30 Hengrui Pharmaceutical
  176. 4.30.1 Hengrui Pharmaceutical Company Information
  177. 4.30.2 Hengrui Pharmaceutical Business Overview
  178. 4.30.3 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  179. 4.30.4 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  180. 4.30.5 Hengrui Pharmaceutical Recent Developments
5 Global Osteoarthritis Pain Drugs Market Scenario by Region
  1. 5.1 Global Osteoarthritis Pain Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Osteoarthritis Pain Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Osteoarthritis Pain Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Osteoarthritis Pain Drugs Sales by Region: 2027-2032
  5. 5.3 Global Osteoarthritis Pain Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Osteoarthritis Pain Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Osteoarthritis Pain Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Osteoarthritis Pain Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Osteoarthritis Pain Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Osteoarthritis Pain Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Osteoarthritis Pain Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Osteoarthritis Pain Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe Osteoarthritis Pain Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Osteoarthritis Pain Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe Osteoarthritis Pain Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Osteoarthritis Pain Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Osteoarthritis Pain Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Osteoarthritis Pain Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Osteoarthritis Pain Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Osteoarthritis Pain Drugs Market Facts & Figures by Country
  41. 5.7.1 South America Osteoarthritis Pain Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Osteoarthritis Pain Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America Osteoarthritis Pain Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Osteoarthritis Pain Drugs Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Osteoarthritis Pain Drugs Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Osteoarthritis Pain Drugs Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Osteoarthritis Pain Drugs Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Osteoarthritis Pain Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Osteoarthritis Pain Drugs Sales by Type (2021-2032) & (M Dose)
  3. 6.1.2 Global Osteoarthritis Pain Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Osteoarthritis Pain Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Osteoarthritis Pain Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Osteoarthritis Pain Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Osteoarthritis Pain Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Osteoarthritis Pain Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Osteoarthritis Pain Drugs Sales by Application (2021-2032) & (M Dose)
  3. 7.1.2 Global Osteoarthritis Pain Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Osteoarthritis Pain Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Osteoarthritis Pain Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Osteoarthritis Pain Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Osteoarthritis Pain Drugs Value Chain Analysis
  2. 8.1.1 Osteoarthritis Pain Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Osteoarthritis Pain Drugs Production Mode & Process
  5. 8.2 Osteoarthritis Pain Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Osteoarthritis Pain Drugs Distributors
  8. 8.2.3 Osteoarthritis Pain Drugs Customers
9 Global Osteoarthritis Pain Drugs Analyzing Market Dynamics
  1. 9.1 Osteoarthritis Pain Drugs Industry Trends
  2. 9.2 Osteoarthritis Pain Drugs Industry Drivers
  3. 9.3 Osteoarthritis Pain Drugs Industry Opportunities and Challenges
  4. 9.4 Osteoarthritis Pain Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst